MSD

News

FDA clears J&J's 2-in-1 tablet for prostate cancer

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

News

AstraZeneca, MSD raise prostate cancer awareness with 'Never...

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co.

Patients

Patient engagement strategies: the pharmaphorum podcast

This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate.

Views & Analysis

The top 5 pharma M&A deals of 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers –

Views & Analysis

How companies can encourage more diversity and inclusion in ...

September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it i

FDA clears J&J's 2-in-1 tablet for prostate cancer

MSD, Moderna start phase 3 trial of mRNA cancer jab

AstraZeneca, MSD raise prostate cancer awareness with 'Never...

Patient engagement strategies: the pharmaphorum podcast

The top 5 pharma M&A deals of 2020

How companies can encourage more diversity and inclusion in ...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

MSD

Editor's Picks